Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
5-Year IF – 2.0, IF – 1.9, JCI (2024) – 0.43
Scopus CiteScore – 4.3
Q1 in SJR 2024, SJR score – 0.598, H-index: 49 (SJR)
ICV – 161.00; MNiSW – 70 pts
Initial editorial assessment and first decision within 24 h

ISSN 1899–5276 (print), ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2019, vol. 28, nr 11, November, p. 1545–1553

doi: 10.17219/acem/104548

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Quality of life and clinical outcomes in Polish patients with high activity rheumatoid arthritis treated with leflunomide (Arava®) in Therapeutic Program: A retrospective analysis of data from the PLUS study

Małgorzata Emilia Tłustochowicz1,B,C,E,F, Bartłomiej Kisiel1,C,D,F, Witold Tłustochowicz1,A,C,E,F

1 Department of Internal Diseases and Rheumatology, Military Institute of Medicine, Warszawa, Poland

Abstract

Background. Rheumatoid arthritis (RA) is a chronic autoimmune disease. Therapy is based on disease-modifying agents. Methotrexate (MTX) is used in first-line therapy and, in the case of failure, its alternatives include leflunomide, which was recommended in Poland within the National Health Fund Therapeutic Program.
Objectives. The purpose of the study was to evaluate the parameters of quality of life of Polish patients with high RA activity during treatment with leflunomide. Additional aims were to evaluate the effectiveness and safety of treatment.
Material and Methods. We performed a retrospective analysis of the data from the PLUS study. The PLUS study comprised 887 adult patients from 30 centers. During the study patients received leflunomide in a maintenance dose of 20 mg or 10 mg once daily. Before the study, 100 mg of leflunomide had been administered daily for 3 days, followed by a maintenance dose of 20 mg/day or 10 mg/day for at least a month before enrollment. The PLUS study observation time was up to 12 months with 1 control visit every 3 months. The patients’ quality of life was assessed with Health Assessment Questionnaire Disability Index (HAQ-DI). Erythrocyte sedimentation rate (ESR), Disease Activity Score (DAS28) and CRP (C-reactive protein) concentration were used to assess the disease activity.
Results. Six hundred seventy-nine patients completed the study. The HAQ-DI decreased after 3 months of observation (mean value 1.46 vs baseline 1.63; p = 0.001) and remained stable. The percentage of patients with HAQ-DI less than 1 and greater than 2 increased from 12.2% to 17.8% and decreased from 33.2% to 20.3%, respectively (p < 0.0001); DAS28 progressively decreased on subsequent visits. C-reactive protein and ESR decreased after 3 months and remained stable. Adverse events were observed in 4.4% of patients.
Conclusion. Treatment with standard leflunomide doses is safe and allows for significant clinical improvement.

Key words

leflunomide, disease-modifying antirheumatic drugs, rheumatoid arthritis

References (33)

  1. Kobelt G, Kasteng F. Access to innovative treatments in rheumatoid arthritis in Europe. A report prepared for the European Federation of Pharmaceutical Industry Associations (EPFIA). Lund University, Sweden; 2009.
  2. Kwiatkowska B, Raciborski F, Maślińska F, Kłak A, Gryglewicz J, Samel-Kowalik P. Early diagnosis of rheumatic diseases: Assessment of the present situation and proposed changes. Reumatologia. 2015;53(1):3–8. doi:10.5114/reum.2015.50550
  3. Smolen J, Landewé R, Breedveld F, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492–509. doi:10.1136/annrheumdis-2013-204573
  4. Singh JA, Saag KG, Bridges Jr SL, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2016;68(11):1–26. doi:10.1002/acr.22783
  5. Canella AC, O’Dell JR. Methotrexate, leflunomide, sulfasalazine, hydro­xychloroquine, and combination therapies. In: Firestein GS, Budd RC, Harris ED, McInnes IB, Ruddy S, Sergent JS, eds. Kelley’s Textbook of Rheumatology. 8th ed. Philadelphia, PA: Saunders Elsevier; 2009:883–908.
  6. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315–324.
  7. Fries JF, Spitz PW, Young DJ. The dimensions of health outcomes: The health assessment questionnaire, disability and pain scales. J Rheuma­tol. 1982;9(5):789–793.
  8. Bruce B, Fries JF. The Health Assessment Questionnaire (HAQ). Clin Exp Rheumatol. 2005;23(5 Suppl 39):S14–S18.
  9. Fransen J, Stucki G, van Riel PLCM. Rheumatoid arthritis measures. Disease Activity Score (DAS), Disease Activity Score-28 (DAS28), Rapid Assessment of Disease Activity in Rheumatology (RADAR), and Rheumatoid Arthritis Disease Activity Index (RADAI). Arthritis Care Res. 2003;49(5S):S214–S224.
  10. Aletaha D, Ward MM. Duration of rheumatoid arthritis influences the degree of functional improvement in clinical trials. Ann Rheum Dis. 2006;65(2):227–233.
  11. Strand V, Singh JA. Improved health-related quality of life with effective disease-modifying antirheumatic drugs: Evidence from randomized controlled trials. Am J Manag Care. 2007;13(Suppl 9):S237–S251.
  12. Singh G, Terry R, Ramey D, Wolfe F, Fries J. Long-term medical costs and outcomes are significantly associated with early changes in disability in rheumatoid arthritis [abstract]. Arthritis Rheum. 1996;39(Suppl 9):S318.
  13. Yelin E, Wanke LA. An assessment of the annual and long-term direct costs of rheumatoid arthritis: The impact of poor function and functional decline. Arthritis Rheum. 1999;42(6):1209–1218.
  14. Strand V, Scott DL, Emery P, et al; Leflunomide Rheumatoid Arthritis Investigators Groups. Physical function and health related quality of life: Analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis. J Rheumatol. 2005;32(4):590–601.
  15. Cohen S, Cannon GW, Schiff M, et al. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Investigator Group. Arthritis Rheum. 2001;44(9):1984–1992.
  16. Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med. 1999;159(21):2542–2550.
  17. Scott DL, Smolen JS, Kalden JR, et al. Treatment of active rheumatoid arthritis with leflunomide: Two year follow up of a double blind placebo controlled trial versus sulfasalazine. Ann Rheum Dis. 2001;60(10):913–923.
  18. Smolen JS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: A double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet. 1999;353(9149):259–266.
  19. Emery P, Breedveld FC, Lemmel EM, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford). 2000;39(6):655–665.
  20. Jagoda JS, Rajapakse CNA. Leflunomide in clinical practice. A retrospective observational study on use of leflunomide in New Zealand. Int J Rheum Dis. 2011;14(4):340–344.
  21. White DHN, Lynskey NV, Jones PB. Leflunomide use in New Zealand. A national prospective post-marketing study. Intern Med J. 2009;39(2):95–102.
  22. Van Roon EN, Jansen TL, Mourad L, et al. Leflunomide in active rheumatoid arthritis: A prospective study in daily practice. Br J Clin Pharmacol. 2004;57(6):790–797.
  23. Ahmad NM, Farman S, Saeed MA, Hameed R, Umair M, Ghafoor E. Leflunomide in Pakistani patients with rheumatoid arthritis: Prospective study in daily rheumatology practice. Int J Rheum Dis. 2011;14(1):48–54.
  24. Chopra A, Saluja M, Lagu-Joshi V, Sarmukadam S. Leflunomide (AravaTM) is a useful DMARD in Indian (Asian) patients: A clinic based observational study of 1-year treatment. Clin Rheumatol. 2008;27(8):1039–1044. doi:10.1007/s10067-008-0897-x
  25. Wiącek R, Kolossa K, Jankowski T, et al. The efficacy and safety of leflunomide in patients with active rheumatoid arthritis. Adv Clin Exp Med. 2012;21(3):337–342.
  26. Kellner H, Bornholdt K, Hein G. Leflunomide in the treatment of patients with early rheumatoid arthritis-results of a prospective non-interventional study. Clin Rheumatol. 2010;29(8):913–920. doi:10.1007/s10067-010-1425-3
  27. Kalden JR, Schattenkirchner M, Sörensen H, et al. The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: A five-year follow-up study. Arthritis Rheum. 2003;48(6):1513–1520.
  28. Kulig M, Malec Z, Tłustochowicz W. Analysis of outpatient methotrexate treatment of patients with rheumatoid arthritis [In Polish]. Reumatologia. 2009;47:202–206.
  29. Tłustochowicz W, Filipowicz–Sosnowska A, Kucharz E, Maśliński W, Wiland P. Care of patients with rheumatoid arthritis in everyday practice of specialist rheumatologist: Results of a nationwide survey [In Polish]. Reumatologia. 2008;46:330–339.
  30. Scott DL, Strand V. The effects of disease-modifying anti-rheumatic drugs on the Health Assessment Questionnaire score. Lessons from the leflunomide clinical trials database. Rheumatology (Oxford). 2002;41(8):899–909.
  31. Strand V, Tugwell P, Bombardier C, et al. Function and health-related quality of life: Results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum. 1999;42(9):1870–1878.
  32. Kalden JR, Scott DL, Smolen JS, et al; European Leflunomide Study Group. Improved functional ability in patients with rheumatoid arthritis: Long-term treatment with leflunomide versus sulfasalazine. European Leflunomide Study Group. J Rheumatol. 2001;28(9):1983–1991.
  33. Poór G, Strand V; Leflunomide Multinational Study Group. Efficacy and safety of leflunomide 10 mg versus 20 mg once daily in patients with active rheumatoid arthritis: Multinational double-blind, randomized trial. Rheumatology (Oxford). 2004;43(6):744–749.
© Wroclaw Medical University